2016年 · 第36卷第08期

At 17: 08 on July 22, 2016, Professor Xiao Shudong, a master of gastroenterology in China, honorary director of Shanghai Institute of Digestive Diseases, and tenured professor of Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine, drove to the west. When the bad news came, all our colleagues in the discipline were as saddened as our colleagues in the national gastroenterology community. Looking back at Professor Xiao's outstanding contributions, I write this article to commemorate it.

Xiao Shudong, master of the World Gastroenterology Organization, chairman of the 6th Chinese Medical Association Gastroenterology Branch, editor-in-chief of the 5th Chinese Journal of Digestion, and tenured professor of Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine, died at the age of 86. When the bad news came, all our colleagues in the editorial department were very saddened.

In 2013, the editorial board of Chinese Journal of Digestion organized some domestic experts, combined with domestic and foreign literature, and based on evidence-based medical evidence, to jointly discuss and draw up China's "Standards for Diagnosis and Treatment of Peptic Ulcer Disease (Shenzhen, 2013)"^[1]。 In recent three years, with the continuous development of science and technology, there have been many new advances in the field of diagnosis and treatment of peptic ulcer. In order to make the "standard of diagnosis and treatment of peptic ulcer" keep pace with the times, it is specially supplemented and updated.

GERD is a digestive tract motility disorder caused by many factors, and its prevalence is increasing year by year. In this study, the patients with GERD who visited the outpatient department of gastroenterology in Fuzhou General Hospital of Nanjing Military Region for the first time were studied. The prevalence and clinical characteristics of three types of GERD in the outpatient department of gastroenterology were discussed by face-to-face interview method, and the related risk factors were analyzed, so as to provide some theoretical basis for the correct prevention, diagnosis and treatment of GERD and its complications.

miRNA not only has significant tumor correlation, tissue specificity and expression stability in gastric cancer tumor tissues, but also has a characteristic miRNA expression profile in the serum of gastric cancer patients. In this study, the latest version of miRNA chip and bioinformatics were used to screen abnormally expressed serum miRNAs, and through preliminary validation methods, the circulating miRNAs associated with gastric cancer were screened out, which provided a possible basis for further searching for peripheral blood molecular markers for early diagnosis of gastric cancer.

A 44-year-old female was admitted to the hospital in April 2014 due to intermittent right lower abdominal pain for 3 years, aggravated with fever for 3 months, and bloody stool for 10 days. Three years ago, the patient began to have intermittent dull pain in the right lower abdomen, once a month, which lasted for several seconds to improve. Three months ago, the patient had fever more than in the afternoon and at night, with a body temperature of 38.5℃, accompanied by dry cough and intermittent dull pain in the right lower abdomen for several minutes; Colonoscopy in an outside hospital showed inflammatory changes in the ileum, protuberant lesions in the cecum, and epithelioid cells in pathological examination. The diagnosis was acute and chronic mucosal inflammation, and anti-infective treatment was ineffective. One month ago, the patient had chills, chills, persistent fever, body temperature reached 39.0℃, and abdominal pain was the same as before; Colonoscopy in other hospitals considered the possibility of CD, and pathological examination showed ulcer and epithelioid nodules; Intestinal CT examination showed multiple segmental wall thickening of the intestinal tube, notably at the terminal ileum; Chest CT showed patch shadows on both upper lungs, PPD was negative, CD was considered, and mesalazine and anti-infective treatment were ineffective. The patient started intravenous infusion of methylprednisolone 80 mg/time, once/d, 17 days before admission, and was treated for 3 days; 40 mg/dose, 1 dose/d, 1 day of treatment; 80 mg/time, once/d for 7 days of treatment. The body temperature was normal during the treatment period, but the body temperature increased again 2 days after the end of treatment. Intermittent use of NSAID was required. The patient developed brown loose stools 10 days ago, 1 to 2 times/d, and the fecal occult blood test was positive. He was given intravenous infusion of infliximab monoclonal antibody (IFX) 200 mg and oral methylprednisolone tablets (trade name Metrola, Pfizer Pharmaceutical Co., Ltd., Italy) 24 mg, all once/d, and was given anti-infective treatment. After 3 days of normal body temperature, he had fever again, more than in the afternoon and at night, and the body temperature was 39.5℃. After administration of indomethacin suppository, the body temperature dropped to normal. The patient had no night sweats, oral and vulvar ulcers, rash, and joint pain since the onset of the disease, and his body weight decreased by 10 kg. Admitted for further diagnosis and treatment.

With changes in dietary lifestyle, the prevalence of chronic constipation is on the rise. Chronic constipation can seriously affect the quality of life of patients and increase the medical burden. Although empirical treatment can be used as a primary treatment option, most treatments have a low level of evidence-based evidence, and approximately half of patients are ineffective to traditional laxative treatment. Therefore, there is an urgent need for new methods to treat chronic constipation.

Dear editor of Chinese Journal of Digestion:

Dear fellow gastroenterologist, Shenzhen Nanshan District People's Hospital: